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Background: The accumulation of beta amyloid (Aβ) peptides, a hallmark of Alzheimer’s disease (AD) is related to
mechanisms leading to neurodegeneration. Among its pleiotropic cellular effects, Aβ accumulation has been
associated with a deregulation of sphingolipid metabolism. Sphingosine 1-phosphate (S1P) derived from sphingosine
is emerging as a critical lipid mediator regulating various biological activities including cell proliferation, survival,
migration, inflammation, or angiogenesis. S1P tissue level is low and kept under control through equilibrium
between its synthesis mostly governed by sphingosine kinase-1 (SphK1) and its degradation by sphingosine
1-phosphate lyase (SPL). We have previously reported that Aβ peptides were able to decrease the activity of
SphK1 in cell culture models, an effect that could be blocked by the prosurvival IGF-1/IGF-1R signaling.
Results: Herein, we report for the first time the expression of both SphK1 and SPL by immunohistochemistry in
frontal and entorhinal cortices from 56 human AD brains. Immunohistochemical analysis revealed a decreased
expression of SphK1 and an increased expression of SPL both correlated to amyloid deposits in the entorhinal
cortex. Otherwise, analysis of brain tissue extracts showed a decrease of SphK1 expression in AD brains whereas
SPL expression was increased. The content of IGF-1R, an activator of SphK1, was found decreased in AD brains as
well as S1P1, the major receptor for S1P.
Conclusions: Collectively, these results highlight the importance of S1P in AD suggesting the existence of a
global deregulation of S1P signaling in this disease from its synthesis by SphK1 and degradation by SPL to its
signaling by the S1P1 receptor.
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Alzheimer’s disease (AD) is a devastating neurodegenera-
tive disorder which is characterized by two principal fea-
tures: i) intracellular accumulation of hyperphosphorylated
tau protein constituting neurofibrillary tangles (NFT) and
neuropil threads; and ii) extracellular accumulation of β-
amyloid (Aβ) peptide, major component of diffuse, focal
and stellate deposits – the focal deposit constituting the
core of the senile plaques [1]. These lesions are likely impli-
cated in neuronal death and synaptic dysfunction associ-
ated with cerebral atrophy and cognitive impairment,
characteristics of AD [2]. According to the stage of the dis-
ease, they can be confined to a specific location (i.e. ento-
rhinal cortex, hippocampus) or be widely distributed in the
brain [3-5]. Even if definite causes are not clearly identified,
several molecular mechanisms have been involved in the
pathogenesis of AD: mutations of APP or of presenilins,
epsilon 4 allele of ApoE, excessive Aβ production and/orFigure 1 Schematic representation of the sphingolipid rheostat in AD
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stress and lipid metabolism alteration [6-9].
Sphingolipids are ubiquitous lipid components of mem-
branes that are metabolized to form signaling molecules
associated with cellular processes important for health
and disease [10,11] (Figure 1). One of the most important
of these metabolites is sphingosine 1-phosphate (S1P),
which regulates pleiotropic biological activities such as
proliferation, survival, migration, inflammation, or angio-
genesis [10,11]. S1P is generated from sphingosine, the
backbone component of all sphingolipids and a pro-
apoptotic sphingolipid [12] in a reaction mainly catalyzed
by the sphingosine kinase isoform 1, SphK1 [13]. In turn,
SpkK1 can be activated by multiple stimuli as IGF-1 sig-
naling [14]. The balance between the levels of S1P and its
metabolic precursors ceramide and sphingosine has been
regarded as a switch that could determine whether a cell
proliferates or dies [15]. S1P can be secreted and signal ascontext. Ceramide can be generated de novo or by hydrolysis of
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(GPCR), named S1P1-5 [16]. These receptors differ in their
tissue distribution and the specific effect of S1P is driven
by the predominance of the S1P receptor subtypes
expressed [16]. Intracellular functions of S1P also exist
with recent studies linking S1P to epigenetic regulation,
calcium mobilization or activation of NF-κB [11,17,18]. Im-
portantly, the agonist-induced S1P production as well as
its downstream effects can be disrupted by inhibition of
SphK1 gene expression or enzymatic activity illustrating
that SphK1 plays a crucial role in the observed cellular ef-
fects played by S1P [19]. S1P can irreversibly be degraded
into hexadecenal and ethanolamine phosphate by sphingo-
sine 1-phosphate lyase (SPL) [20]. Interestingly, recent clin-
ical observations have suggested an inverse relationship
between SPL and SphK1 activities on the level of S1P in
prostate cancer specimens implying that the overall in-
creased S1P level commonly observed in cancer does not
merely reflect overexpression of SphK1 activity, but could
also be a consequence of loss of SPL expression [21].
In the brain, alteration of sphingolipid metabolism is
believed to be essential for neuronal function as evi-
denced in a number of severe disorders besides AD includ-
ing Niemann Pick disease, amyotrophic lateral sclerosis,
Parkinson and AIDS dementia [24]. With regard to AD,
most of the post-mortem studies have examined the level
of ceramide and sphingosine, the pro-apoptotic precursors
of sphingosine 1-phosphate, or enzymes responsible for
their generation such as acid sphingomyelinase (which
degrades sphingomyelin to ceramide) or acid ceramidase
(which converts ceramide to sphingosine). For instance,
acid sphingomyelinase activity and ceramide content are
increased in the frontotemporal area [25-28]. A positive
correlation was found between acid sphingomyelinase ac-
tivity and Aβ or phosphorylated tau in this region, sug-
gesting that increased ceramide levels are associated with
AD pathology [24]. The involvement of sphingosine is un-
clear with either increased [25,29] or decreased [22,26]
content in AD as compared to normal brains. On the con-
trary, one clinical study has reported a decrease in S1P ex-
pression in AD tissues [22]. Interestingly, this decrease of
S1P level was negatively correlated with Aβ and phosphor-
ylated tau protein levels [22]. Moreover, ceramide level
has been reported to be increased in CSF from patients
with moderate severity of AD [30] whereas low levels of
plasmatic ceramide have been reported in the early stages
of memory impairment [31,32]. Thus, the levels of these
sphingolipids might be related to disease stage and repre-
sent an interesting pool of biomarkers for AD.
In cell culture models, a wealth of studies have firmly
established the deleterious effect of ceramide on glial
and neuronal cells exposed to Aβ peptides [26,33,34]. In
addition to mediate the pro-apoptotic effect of Aβ, cer-
amide can also promote Aβ biogenesis by activating andstabilizing BACE-1 [35]. Conversely, S1P protects neur-
onal cells from apoptosis [36] notably in response to Aβ
peptides [33]. Moreover, SphK1/S1P signaling was found
to be a major transducer of two important growth fac-
tors, IGF-I and TGF-β1, whose neuroprotective effects
against Aβ are well recognized [33,37-39]. With regard
to the S1P receptors S1P1-5 [11], their contribution to
AD has not yet been investigated. However, FTY720, an
agonist of S1P1,3,4,5, developed as an immunomodulatory
drug and currently prescribed for multiple sclerosis, is
able to restore passive avoidance memory in a rat model
of AD as efficiently as Memantine, a finding supporting
the existence of a direct action of this drug on neurons
through S1P receptors [40].
Herein, we report for the first time the expression of
SphK1 and SPL, the two main enzymes controlling the
level of S1P, in frontal and entorhinal cortices of brains
from AD patients, and their interaction with Aβ deposits
distribution in the cortical layers. The expression of
SphK1 and SPL was also assessed by western blot on brain
tissue extracts together with SphK2, the minor isoform of
sphingosine kinase, and S1P1, the most important S1P re-
ceptor and IGF-1R, whose activation promotes activation
of SphK1 and production of S1P.
Methods
Human brain tissues
Human brain tissues were provided by certified French
biological resource centers from Lille (DC-2008-642),
Paris (DC-2009-957) and Toulouse (AC-2009-973), and
by the national brain bank GIE Neuro-CEB (AC-2007-5).
This study is compliant with the Helsinki Declaration and
has been approved by CPP (Comité de protection des per-
sonnes du Sud-Ouest et Outre-Mer I) ethical committee
(PHRC 1802, #1-09-54). Post-mortem tissues from 56 AD
patients were included in the imunohistochemical study
(Table 1). Once extracted, hemi-brains were fixed with
formalin (4% in PBS) during approximately 1 month. Sam-
ples from frontal and entorhinal cortices were embedded
in paraffin. These blocks were cut serially to obtain 4 μM
sections. The diagnosis of AD was made according to
current criteria of NIA – Alzheimer’s Association [41].
The assessment included Braak and Thal staging. For im-
munoblots, fresh samples (independent from those used
for immunohistochemical study) from frontal cortex and
hippocampus of 4 AD cases and 3 non demented age-
mached controls were used (Table 2).
Immunohistochemistry
Paraffin-embedded, formalin-fixed sections were depar-
affinized in xylene, rehydrated in graded ethanol and
washed for 5 min with Tris buffer saline (pH 7.6). Anti-
gen retrieval was performed by immersing sections in
boiling EDTA buffer (pH 9.0). Endogenous peroxidase
Table 1 Characteristics of patients included in the
immunohistochemistry study
Variable AD patients (N=56)
Age at death (years)
Median [IQR] 80.0 [72.0-87.0]
Range 56.0, 96.0




Median [IQR] 26.5 [19.0-34.0]
Range 3.0, 96.0
Missing (n) 4
Braak Stage – n of patients (%)
IV 1 (1.8)
V-VI 55 (98.2)





Table 2 Characteristics of patients included in the
immunoblot study
Variable Controls (N = 3) AD patients (N = 4)
Age at death (years)
Median [IQR] 73.0 [69.0-92.0] 73.0 [72.0-73.0]
Range 69.0-92.0 72.0, 89.0
Sex – n of patients (%)
Female 1 (33.3) 2 (50.0)
Male 2 (66.6) 2 (50.0)
Post mortem interval
Median [IQR] 36.5 [10.0-63.0] 56.5 [44.0-59.0]
Range 10.0-63.0 44.0, 59.0
Missing (n) 1
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the sections for 10 min in Dual Endogenous Enzyme
Block (Dako, Denmark). Double staining was carried out
to evaluate the expression of SphK1 and the density of
amyloid deposits (n = 56). Double staining was also
carried out to evaluate the expression of SPL together
with the density of amyloid deposits in 10 cases ran-
domly selected. Sections were initially incubated with
primary antibody directed against amyloid beta (mouse
clone 6 F/3D, 1:100, Dako) during 2 hours at room
temperature (RT). Sections were washed twice during
7 minutes in Tris-buffered NaCl solution with Tween
20 (pH 7.6, Dako). Immunostaining was revealed using
BrightVision poly HRP-Anti-Mouse IgG (Immuno-
logic, Netherland) during 30 min at RT and treated
with diaminobenzidine/hydrogen peroxide (DAB) for
10 minutes (DAB + Liquid, Dako). Sections were rinsed
for 5 minutes in tap water and then rinsed rapidly in dis-
tillated water. After this first step, sections were washed
for 10 minutes with Tris buffer saline (pH 7.6) before
incubation with primary antibody directed against
SphK1 (rabbit polyclonal, 1:500, [21,42]) or SPL (rabbit
polyclonal #HPA023086, 1:250, Sigma Aldrich) overnight
at 4°C. The sections were washed twice during 7 minutes
in Tris-buffered NaCl solution with Tween 20 (pH 7.6,
Dako). Immunostaining was exposed using BrightVision
poly AP-Anti-Rabbit IgG (Immunologic, Netherland)
during 30 minutes at RT and treated with Liquid Fast
Red (Abcam) for 30 minutes. Sections were counter-
stained with hematoxylin in alcohol solution. Slides
were then mounted in Faramount Aqueous Mounting
Medium (Dako).
Qualitative and quantitative examination
Once mounted, slides were scanned with a digital scanner
NanoZoomer (HAMAMATSU, Réf: 2.0-RS: C10730-13) to
obtain high resolution virtual slides. Digitalized slides were
analyzed with NDP View 2.0 software (HAMAMATSU).
Morphometric investigation was carried out by two ob-
servers (M. B. Delisle & J. Ceccom) to determine the nu-
merical density of amyloid deposits and of neurons
expressing SphK1 or SPL at two levels: negative or mild
(+) and strong (++) among the different cortical layers.
Columns constituted of contiguous microscopic fields,
from the pial surface to the white matter were drawn on
each slide. As the fields were examined at a magnification
of x400, each field was 300 μM × 150 μM in size. As the
thickness of the cortex appeared to be variable between the
different sections, after the counting step, the columns
were standardized to 10 fields [43]. Field 1 corresponded to
the cortex immediately under the pial surface and field 10
reached the white matter (Additional file 1). In each field,
the number of profiles of Aβ deposits, of neurons and of
neurons expressing low level (+) and high level (++) of
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base. For Aβ deposits, focal and diffuse plaques were re-
corded separately according to published discriminating
features [1].
Preparation of human brain homogenates and
Western blotting
Frozen tissue samples were pulverized with “Mikro-
Dismembrator” (Sartorius, France) and resuspended in
lysis SDS sample buffer (50 mM Tris-HCl pH 6.8, 5%
SDS, 10% glycerol and Complete EDTA-free protease
inhibitor cocktail (Roche)). Samples were sonicated at
4°C then centrifuged at 13,000 × g for 10 minutes. Total
protein concentration was assessed on the supernatant
with the BCA Protein Assay (Interchim). Samples were
prepared for electrophoresis by adding 5% β-mercapto-
ethanol, 0.05% bromophenol blue and heating at 98°C
for 3 minutes. Sixty μg of total proteins were loaded
into each lane of a 10% polyarcrylamide gel and electro-
phoresed at 50 V in a MiniProtean Tetra System (Bio-Rad
Laboratories, Irvine, CA, USA). After migration and
10 min of transfer with the Transblot Turbo (Bio-Rad
Laboratories), nitrocellulose membranes were blocked with
4% skimmed milk, and washed 3 times with Tris-buffered
saline buffer containing 0,05% Tween-20 (TBST). Blots
were probed with either SphK1 (rabbit polyclonal #71700,
1:1000, Abcam), SphK2 (rabbit polyclonal #37977, 1:1000,
Abcam), SPL (rabbit polyclonal #HPA023086, 1:2,000,
Sigma Aldrich), S1P1 (rabbit clone EPR4538(2) #NBP1-
95120, 1:5,000, Novus) and IGF-1R (mouse clone
3G5C1 #MAB10693, 1:2,000, Abnova) antibodies. After
an overnight incubation at 4°C, the membranes were
washed with TBST, labeled with a peroxidase-conjugated
anti-rabbit or anti-mouse (dilution 1:3,000) secondary
antibody (Clontech) and revealed by chemiluminescence
(Clarity kit, Bio Rad). The density of the band of β–actin
(anti-β-actin monoclonal antibody, AC-15, Sigma-Aldrich,
1:10,000) was used to normalize the signals.
Data analysis
Statistical analysis was carried out with a multilevel linear
mixed model to take into account non independent data
(eight fields into two cerebral areas per subject were
studied). Due to the poor representativeness of fields 1
non tissular zone and pial surface) and 10 (proximal
white matter), they were not included in statistical ana-
lysis. As a strong relationship between the number of neu-
rons and SphK1 expression was guaranteed because of
mathematical coupling (ie the number of neuron express-
ing SphK1 in a specific field depends on the number of
neurons observed in this same field), the relation between
total number of neurons and SphK1 expression was esti-
mated using the method of Oldham [44]. Correlations
were estimated as significant at p < 0.05. The analysis wasperformed using “Stata 11.2 Statistical Software” (Stata
Corporation, College Station, TX, USA).
Results
Immunohistochemical study
Most of the subjects were staged Braak V-VI and Thal 4
to 5, therefore the packing density of neurofibrillary tan-
gles and senile plaques was high (Table 1). Cortical
thickness variability was noticed and could be related to
atrophy which is a common feature in AD. Morpho-
logical study showed a distribution of cortical layers over
the 10 fields standardized columns which was consistent
with literature [1,43]. For instance, in frontal and entorhi-
nal cortex, cortical layer I was principally found in fields 1
and 2, cortical layers II & III were mostly represented in
fields 2 to 6, layer IV was confined in fields 6 to 8, and
layers V & VI was found in fields 7 to 10. The distribution
of neurons over cortical layers was different as expected
and did not follow the same pattern in the two studied cor-
tical regions. Namely, in frontal cortex, the number of neu-
rons was constant over layers II to V whereas their packing
density was more fluctuant in entorhinal cortex. The distri-
bution of Aβ deposits was consistent with the laminar dis-
tribution previously reported [1,43], namely a higher
numerical density in cortical layers II and III (data not
shown). Moreover, in our cohort, focal deposits were more
represented than diffuse ones in frontal (β = 1.7; p < 0.001)
and entorhinal (β = 1.08; p < 0.001) cortices, which is con-
sistent with advanced stage of AD. SphK1/SPL staining
was mainly observed in neurons (Figure 2).
Correlation between density of neurons and Aβ deposits
The packing density of neurons and Aβ deposits were un-
correlated in the frontal cortex (β= 0.049; p = 0.67) and
inversely correlated in the entorhinal cortex (β= -0.34;
p = 0.019). This negative correlation was only related to the
presence of focal deposits (β = -0.39; p = 0.021) while diffuse
ones were not found to impact the density of neurons
(β= -0.17; p = 0.645). These results indicate an overall effect
of Aβ focal deposits on neuronal density solely observable
in entorhinal cortex which is consistent with morphological
observations characteristics of end stage AD patients.
Correlation between Aβ deposits and SphK1 expression in
AD brain
The packing density of neurons in which SphK1 expres-
sion was high (SphK1++) was not correlated with Aβ de-
posits density in the frontal cortex (β = 0.04; p = 0.62)
whereas it was inversely correlated in the entorhinal cor-
tex (β = -0.77; p < 0.001) (Figure 3). This negative correl-
ation was only related to the presence of focal deposits
(β = -0.88; p < 0.001) while diffuse ones were not found
to impact the density of neurons expressing Sphk1 at
high level (β = -0.33; p = 0.218).
Figure 2 Immunohistochemical study of SphK1/SPL expression and Aβ deposits. (a) Double labeling of SphK1 and Aβ in AD brain section
from entorhinal cortex. Diffuse and focal deposits are seen in different areas. X200. Inset: Strongly stained neurons (SphK1++, black arrow) and
mild stained neurons (SphK1+, white arrow) are clearly distinguishable. X400 (b) Double labeling of SPL and Aβ in AD brain section from
entorhinal cortex. A senile plaque is mainly surrounded by strong labeled neurons (SLP++). X400.
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brain
The packing density of neurons with strong expression of
SPL (SPL++) and the packing density of Aβ deposits were
not correlated in the frontal cortex (β = -0.11; p = 0.72)
whereas a significant correlation was found in the entorhi-
nal cortex (β = 0.49; p = 0.014) (Figure 4). This positive
correlation was only related to the presence of focal de-
posits (β = 0.85; p = 0.004) while diffuse ones were not
found to impact the density of neurons expressing SPL at
high level (β = - 0.47; p = 0.43).
Correlation between SphK1 expression and total neurons in
AD brain
Statistical analysis revealed that SphK1 expression and
total density of neurons were correlated in frontal cor-
tex (β = 0.54; p < 0.001) and entorhinal cortex (β = 0.27;
p < 0.001).Figure 3 Correlation between neurons with strong expression of Sph
density of Aβ deposits are not correlated in frontal cortex. (b) A negative c
density of Aβ deposits is observed in entorhinal cortex. Data are representeImmunoblot analysis
Each tissue lysate from frontal cortex and temporal cor-
tex in the hippocampal area of AD and control brains
(Table 2) was prepared to quantify the amount of SphK1
and SPL protein. In line with the immunohistochemistry
analysis, there was a marked decrease in SphK1 content
in AD extracts as compared to control (Figure 5). On
the contrary, SPL expression was higher in AD extracts
as compared to control especially in entorhinal cortex
(Figure 5). We next assessed the level of SphK2, the
other sphingosine kinase isoform but its expression was
not different between AD and control samples (data not
shown). Importantly, the expression of the S1P1 recep-
tor, which notably mediates cell survival in response to
S1P in various cell systems and whose expression is ubi-
quitous, was reduced in frontal and entorhinal cortex
(Figure 5). Finally, a marked decrease in IGF-R1 expres-
sion was observed in AD samples (Figure 5).K1 and Aβ deposits. (a) Packing density of SphK1++ neurons and
orrelation between the packing density of SphK1++ neurons and the
d as scatter plot with regression line.
Figure 4 Correlation between neurons with strong expression of SPL and Aβ deposits. (a) Packing density of SPL++ neurons and density
of Aβ deposits are not correlated in frontal cortex. (b) A positive correlation between the packing density of SPL++ neurons and the density of
Aβ deposits is observed in entorhinal cortex. Data are represented as scatter plot with regression line.
Figure 5 Immunoblot analysis of SphK1, SPL, S1P1 and IGF-1R. Tissue lysates from frontal cortex (a) and temporal cortex in the hippocampal
area (b) of AD and control brains were assayed for SphK1, SPL, S1P1 and IGF-1R expression. Equal loading of protein was monitored using
antibody to β-actin. The intensity of each band was quantified using ImageJ software and is provided as representative under corresponding
blot. Values are expressed at 1/1000.
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While cancers are associated with alterations of cellular
cycle inducing anarchic proliferation, neurodegenerative
diseases are on the contrary associated with a cellular
deregulation leading to neuronal death. As recently
shown in a cohort study, elderly people suffering from
cancer have a reduced risk of AD dementia and vice
versa [45]. This observation underlines the existence of a
relationship between these two major mechanisms of
cellular function impairment. Interestingly, SphK1 over-
expression leading to increase S1P signaling has been
demonstrated to have an important role in cancer initi-
ation, progression and resistance to therapeutics [13],
whereas high levels of ceramide have been reported in
AD brains [24]. Thus, in cancer and neurodegenerative
diseases like AD, two opposite cellular fate outcomes
could result from the imbalance of ceramide/S1P biostat
[15]. Recently, Brizuela and coworkers reported that
SphK1 expression was upregulated whereas SPL expres-
sion was downregulated in prostatic cancer. This original
result showed that abnormal S1P level in prostatic ma-
lignant cells was not only related to overproduction by
SphK1 but also to an important impairment of the elimin-
ation pathway provided by SPL [21]. In our study we re-
ported the opposite situation, and showed for the first time
that in AD, SphK1 expression was downregulated whereas
SPL expression was upregulated. As a consequence of this
deregulation, S1P levels should be decreased in cells and
drive them to neurodegenerative processes.
In 2010, He and coworkers provided crucial informa-
tion about the levels of ceramide and S1P in AD brains
and assessed the expression level of enzymes implicated
in ceramide/S1P metabolism but not SphK1 nor SPL
[22]. The authors showed that Aβ was able to interact
with sphingomyelinase and could induce in fine a de-
crease of S1P level. On the other hand, in vitro studies
showed that Aβ, under oligomeric or fibrillary form,
could trigger ceramide mediated apoptosis [22,46]. The
lack of information about SphK1 and SPL in AD and
their direct involvement in S1P metabolism led us to in-
vestigate their expression within AD brains and to assess
their possible relationship with Aβ deposits which repre-
sent one of the principal hallmarks of this disease.
Western blot analysis showed that SphK1 expression was
reduced in AD brains compared to non demented controls.
This observation supports the idea that neuropathologic
processes related to AD and especially Aβ accumulation
may induce deleterious effects on the expression of princi-
pal actors of the sphingosine 1-phosphate metabolism.
SphK2 which is largely less implicated in the overall pro-
duction of S1P than SphK1 did not show any particular
modification of its expression in AD brains which is con-
sistent with literature [47]. Morphologically, SphK1 expres-
sion was dramatically decreased within neurons populatingfields in which the density of Aβ deposit was the highest.
These fields corresponded predominately to cortical layers
II, III where neuritic plaques are preferentially found [43]
and extended to layer IV. This result was significant for
neurons from entorhinal cortex that are very vulnerable
[48], whereas neurons from frontal cortex seemed to be
more resilient to Aβ toxicity. However, the packing density
of total neurons in frontal and entorhinal cortices was cor-
related with the packing density of neurons with high ex-
pression of SphK1. As SphK1 expression is related to
survival effects, its downregulation in AD could induce an
opposite outcome. We previously showed that SphK1 ac-
tivity was also reduced when cultured cells were exposed
to fibrillary Aβ 25-35 [33]. All these results tend to demon-
strate that Aβ deposits are directly involved in the reduc-
tion of S1P production by modulating the expression and
the activity of SphK1 and could eventually shift the death/
survival balance in favor of neurodegenerative processes.
Inversely, SPL which is the final enzyme in the sphingo-
lipid degradative pathway controls the only exit point for
sphingolipid intermediates. In addition to regulating S1P
levels, SPL is a gatekeeper of a critical node of lipid meta-
bolic flow [20]. In our study, Western Blot examination of
SPL expression showed a higher level of this enzyme in
AD brains compared to controls. This observation sug-
gests that SPL could be highly deregulated in AD and is
consistent with literature that reported upregulation of
SPL mRNA expression in AD brains correlated to pro-
gression of dementia [28]. Our immunohistological study
on ten AD cases confirmed these data and provided com-
plementary information. Aβ deposits packing density was
not correlated with high expression of SPL within neurons
from frontal cortex but was positively correlated with high
expression of SPL within neurons from entorhinal cortex.
Notably, SPL deficiency leads to resistance against apop-
tosis induced by chemotherapy or nutriment starvation
[21,49]. In AD, two single nucleotide polymorphisms were
detected in the sgpl1 gene in late-onset AD, which sug-
gests that variation in sgpl1 expression and/or function
may confer susceptibility to late-onset AD [50]. Our data
indicates that increase of SPL expression in AD could be
one of the consequences of Aβ accumulation. Hexadece-
nal and phospho-ethanolamine produced by SPL from
S1P degradation have been reported to induce apoptosis,
among other effects [51]. As suggested by Aguilar and
Saba in 2012, SPL upregulation may be involved in accu-
mulation of hexadecenal which could induce neurological
and cognitive defects in some pathologies as for example
in Sjögren-Larsson syndrome. This hypothesis suggests an
important involvement of SPL deregulation in the patho-
genesis of AD and leads to consider this enzyme as a
promising therapeutic target.
SphK1 activation is modulated by many agonists in-
cluding IGF-1 which induces the translocation of SphK1
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http://www.actaneurocomms.org/content/2/1/12to the plasma membrane [52]. In a previous study, we
showed that the deleterious effect of Aβ exposition on
SphK1 activity could be reversed by adjunction of IGF-1
to the culture medium [33]. Here we show that IGF-1R
expression is dramatically reduced in frontal and hippo-
campal regions of AD cases compared to controls. This
result is consistent with literature [23] and introduces a
possible candidate for mediating signaling between Aβ
and SphK1. Post-mortem studies on AD brains showed
that IGF-1 deficiency and resistance is related to the
stage of the disease and then could be considered as
causal in the pathogenesis of AD [23]. IGF-1R impair-
ments lead to brain amyloidosis in rodents and IGF-1R
confers to cells the ability to reduce exogenously applied
oligomers [53,54]. This suggests that IGF-1R disorders
are involved in Aβ accumulation and subsequent synap-
tic loss [55]. Here, we face a vicious circle in which Aβ
induces a deregulation of IGF-1 signaling that in turn
leads to overproduction of Aβ.
As S1P is able to trigger intracellular signaling pathways,
it is also involved in an extracellular autocrine/paracrine
signaling through five S1P receptors. Now well described,
these receptors are involved in a wide range of signaling
pathways including proliferation, survival, migration and
cell-cell interactions [16]. Here we focused on S1P1 as it is
the most represented in brain and its activation can lead
to an increase of survival/prevention of apoptosis through
PI3K and Akt signaling [56]. The important decrease of
S1P1 expression in AD cases reported in our study could
be related to a deregulation of S1P extracellular signaling
induced by Aβ accumulation. This hypothesis is consistent
with recent study which showed that FTY720, an agonist
of S1P receptors with high affinity for S1P1 was able to
reverse behavioral impairment in rat model of AD [40].
Conclusion
In conclusion, our data extend previous in vitro findings
regarding the effect of Aβ deposits on sphingolipid rheo-
stat and show for the first time the decreased expression
of SphK1 in AD brains. They provide the first evidence
of increased expression of SPL related to amyloid de-
posits in a human neurodegenerative disease. Taken to-
gether, these original data reveal an imbalance in SphK1/
SPL system which might play a crucial role in neuro-
degenerative disease. As cells are very sensitive to varia-
tions of S1P levels, the assessment of such variations in
AD or early stages of memory impairment could be a
promising prognostic tool as a biomarker in fluids.
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